Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial

Dörner, ThomasKaul, MartinSzántó, AntóniaTseng, Jui-ChengPapas, Athena S.Pylvaenaeinen, IlonaHanser, MalikaAbdallah, NasriGrioni, AndreaSantos Da Costa, AidaFerrero, EnricoGergely, PéterHillenbrand, RainerAvrameas, AlexandreCenni, BrunoSiegel, Richard M.2023-12-202023-12-202023Annals Of The Rheumatic Diseases. -[Epub ahead of print] (2023). -Ann. Rheum. Dis. - 0003-49670003-4967https://hdl.handle.net/2437/364092Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trialfolyóiratcikkopen access articlehttps://ebib.lib.unideb.hu/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM117457OrvostudományokKlinikai orvostudományokhttps://ard.bmj.com/lookup/doi/10.1136/ard-2023-224691szerzőhttp://dx.doi.org/10.1136/ard-2023-2246912023-12-2000110255690000185179435080